Search

New research published in The New England Journal of Medicine finds adding the immunotherapy drug pembrolizumab (Keytruda®) to standard chemotherapy greatly improves outcomes in people with advanced endometrial cancer. The phase 3 study was overseen by MSK gynecologic medical oncologist Carol Aghajanian.

… Monday, March 27, 2023 Endometrial cancer , which makes up about 90% of uterine cancers, will be diagnosed in more than 65,000 people in the United States this year. It is the fourth most common cancer in women and is one of the few cancers that is increasing in incidence and mortality. Unfortunately

Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough advances in new treatment approaches for several cancer indications at the 2023 ASCO Annual Meeting held June 2 to 6, 2023. Highlights of practice-changing study results in glioma, rectal cancer, non-small cell lung cancer, biliary tract cancer, and more were as follows:

… Tuesday, June 6, 2023 Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough advances in new treatment approaches for several cancer indications at the 2023 ASCO Annual Meeting held June 2 to 6, 2023. Highlights of practice-changing study results in glioma, rectal cancer, non-small

Meet Lisa DeAngelis, MSK's new Physician-in-Chief. She discusses her upbringing, her early career at MSK, and her top priorities as physician-in-chief.

… Thursday, January 2, 2020 Summary Lisa DeAngelis, the new Physician-in-Chief, has deep roots at MSK. After more than 30 years at Memorial Sloan Kettering, Lisa DeAngelis still gets up at 6 a.m. , goes to the gym if she’s feeling ambitious, and walks to and from work with her husband, Peter Okin, a cardiology

Thank you to our donor community. Your commitment to supporting Memorial Sloan Kettering Cancer Center (MSK) is essential to advancing our mission.

… Friday, April 1, 2022 Thank you to our donor community. Your commitment to supporting Memorial Sloan Kettering Cancer Center (MSK) is essential to advancing our mission. Read more to learn about your impact. Fundraising Events at MSK Cycle for Survival’s 2022 Season and 2021 Allocations Cycle for Survival

MSK is proud to announce that four Sloan Kettering Institute (SKI) researchers have been named 2025 Kravis WISE fellowship grant recipients.

… Tuesday, March 11, 2025 MSK is proud to announce that four Sloan Kettering Institute (SKI) researchers have been named 2025 Kravis WISE fellowship grant recipients. This year’s winners are postdoctoral fellows  Almudena Chaves-Pérez, PhD , and Adriana Mujal, PhD , and graduate students  Hina Shah and

Researchers have discovered uncanny similarities between cells found in brain tumors and a type of stem cell that’s important for building the brain during fetal development.

… Thursday, February 20, 2020 VIDEO | 00:24 Jumping nucleus in brain tumor cells This video shows the division in cells within organoid-like structures. A cell with a jumping nucleus is highlighted in yellow, and the cell bodies are tracked by a yellow arrow. The cells dividing in place with and without

… Wednesday, April 19, 2023 Memorial Sloan Kettering Cancer Center (MSK) experts presented findings from their latest clinical, translational, and foundational cancer research at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14 to 19 in Orlando, Florida. Highlights

Scientists have identified genes and biological mechanisms that one day could be targeted with drugs to stop kidney cancer from spreading to the bone, brain, or other organs.

… Wednesday, December 19, 2012 Summary Scientists have identified genes and biological mechanisms that one day could be targeted with drugs to stop kidney cancer from spreading to the bone, brain, or other organs. Metastasis , the process by which some tumors spread from their site of origin to other body

After an extensive nationwide search, Memorial Sloan Kettering Cancer Center (MSK) announced today that Lisa M. DeAngelis has been named Physician-in-Chief and Chief Medical Officer. A leading expert in brain cancer, Dr. DeAngelis previously served as Chair of the Department of Neurology and was co-founder of MSK’s Brain Tumor Center during her 30-plus-year tenure at the institution.

… Tuesday, September 10, 2019 Lisa M. DeAngelis Has Been Named Physician-in-Chief and Chief Medical Officer of MSK Lisa M. DeAngelis Has Been Named Physician-in-Chief and Chief Medical Officer of MSK After an extensive nationwide search, Memorial Sloan Kettering Cancer Center (MSK) announced today that

During the upcoming ASCO Virtual Scientific Program, MSK Medical Oncologist Zsofia K. Stadler, MD, will present a study where she and her team sought to assess the clinical utility of germline mutation profiling for targeted therapeutic interventions in a pan-cancer patient population, or a population with similarities and differences among the genomic and cellular alterations found across their diverse tumor types.

… Friday, May 29, 2020 During the American Society of Clinical Oncology (ASCO) Virtual Scientific Program , Memorial Sloan Kettering (MSK) Medical Oncologist Zsofia K. Stadler, MD , will present a study where she and her team sought to assess the clinical utility of germline mutation profiling for targeted